Translate page

Pediatr Blood Cancer. 2014 Feb;61(2):355-7. doi: 10.1002/pbc.24521. Epub 2013 Sep 17.


Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M.




Imatinib can be safely discontinued in adults with chronic myeloid leukemia (CML) where there is a prolonged complete molecular response (CMR). No data are available in the pediatric population. Six children with CML discontinued imatinib by themselves. Only three of them were in CMR but for <2 years. A significant increase in transcript level was observed in all six patients after cessation of imatinib and five patients lost the major molecular response (MMR). Four patients regained the MMR within 3 months. Cessation of imatinib in children is not recommended outside a trial, particularly in patients without prolonged CMR.
© 2013 Wiley Periodicals, Inc.